ThromboGenics Ltd. Promoted to the NEXT 150 Index

Leuven, Belgium – 30 June, 2009 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the Company has been promoted to the NEXT 150 index on the Euronext stock exchange.

ThromboGenics’ inclusion in the NEXT 150 index reflects the strong share price performance and progress that the Company continues to make. The inclusion of the Company in the NEXT 150 index also follows the Company entering the VLAM-21 index earlier in the year, which is a capitalized-weighted index of the 21 most capitalized Flemish stocks that are traded on a stock exchange.

The NEXT 150 index comprises mid to large capitalisation stocks on the Euronext exchange. The index consists of the 150 next largest stocks following the Euronext 100 index and includes stocks from the Amsterdam, Brussels, Lisbon and Paris exchanges of Euronext.

ThromboGenics will be included in the NEXT 150 index as of July 1st, 2009.

Patrik De Haes, CEO of ThromboGenics, commented, “We are very pleased to be included in the NEXT 150 index which reflects the tremendous progress ThromboGenics has made since its inception. The inclusion in the index will further increase the Company’s access to a wide pool of investors and enhance ThromboGenics’ strong profile as one of the leading biotechnology companies in Europe.”